Literature DB >> 12112010

Inhibition of the p38 pathway upregulates macrophage JNK and ERK activities, and the ERK, JNK, and p38 MAP kinase pathways are reprogrammed during differentiation of the murine myeloid M1 cell line.

J Perry Hall1, Roger J Davis.   

Abstract

Mitogen-activated protein (MAP) kinases have been implicated as important mediators of the inflammatory response. Here we report that c-Jun NH(2)-terminal kinase (JNK), extracellular signal-regulated kinase (ERK), and p38 MAP kinase activities are reprogrammed during the IL-6 induced macrophage-like differentiation of the murine myeloid M1 cell line. Moreover, p38 inhibition upregulates JNK and ERK activity in M1 cells and in thioglycollate-elicited peritoneal exudate macrophages. IL-6-induced M1 differentiation also induces expression of the anti-inflammatory cytokine IL-10, and p38 inhibition potentiates this increase in IL-10 expression in an ERK-dependent manner. Thus, we speculate that during inflammatory conditions in vivo macrophage p38 may regulate JNK and ERK activity and inhibit IL-10 expression. These data highlight the importance of p38 in the molecular mechanisms of macrophage function. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12112010     DOI: 10.1002/jcb.10187

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  10 in total

1.  Blocking epidermal growth factor receptor activation by 3,3'-diindolylmethane suppresses ovarian tumor growth in vitro and in vivo.

Authors:  Prabodh K Kandala; Stephen E Wright; Sanjay K Srivastava
Journal:  J Pharmacol Exp Ther       Date:  2011-12-28       Impact factor: 4.030

2.  Role of MLK3 in the regulation of mitogen-activated protein kinase signaling cascades.

Authors:  Deborah Brancho; Juan-Jose Ventura; Anja Jaeschke; Beth Doran; Richard A Flavell; Roger J Davis
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

3.  Feedback control of the protein kinase TAK1 by SAPK2a/p38alpha.

Authors:  Peter C F Cheung; David G Campbell; Angel R Nebreda; Philip Cohen
Journal:  EMBO J       Date:  2003-11-03       Impact factor: 11.598

4.  Inhibition of p38 mitogen-activated protein kinase augments progression of remnant kidney model by activating the ERK pathway.

Authors:  Ryuji Ohashi; Takahiko Nakagawa; Susumu Watanabe; John Kanellis; Ramona G Almirez; George F Schreiner; Richard J Johnson
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

5.  Diverse patterns of cyclooxygenase-independent metalloproteinase gene regulation in human monocytes.

Authors:  Buket Reel; Graciela B Sala-Newby; Wei-Chun Huang; Andrew C Newby
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

6.  LPS induces IL-10 production by human alveolar macrophages via MAPKinases- and Sp1-dependent mechanisms.

Authors:  Hugues Chanteux; Amélie C Guisset; Charles Pilette; Yves Sibille
Journal:  Respir Res       Date:  2007-10-04

7.  A Speculative Role for Stromal Gastrin Signaling in Development and Dissemination of Pancreatic Ductal Adenocarcinoma.

Authors:  Gail L Matters; Gary A Clawson
Journal:  Pancreat Disord Ther       Date:  2013-04-07

8.  Pseudomonas aeruginosa induces p38MAP kinase-dependent IL-6 and CXCL8 release from bronchial epithelial cells via a Syk kinase pathway.

Authors:  Matthew S Coates; Eric W F W Alton; Garth W Rapeport; Jane C Davies; Kazuhiro Ito
Journal:  PLoS One       Date:  2021-02-01       Impact factor: 3.240

9.  IL-17 intensifies IFN-γ-induced NOS2 upregulation in RAW 264.7 cells by further activating STAT1 and NF-κB.

Authors:  Qiyue Gao; Yang Liu; Yan Wu; Qiang Zhao; Lijun Wang; Shanshan Gao; Wen Wen; Weiping Zhang; Ning Guo; Juan Zhou; Zuyi Yuan
Journal:  Int J Mol Med       Date:  2015-12-11       Impact factor: 4.101

Review 10.  Disruption of prostate epithelial differentiation pathways and prostate cancer development.

Authors:  Sander B Frank; Cindy K Miranti
Journal:  Front Oncol       Date:  2013-10-31       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.